PMID- 36219900
OWN - NLM
STAT- MEDLINE
DCOM- 20221116
LR  - 20230103
IS  - 1872-7123 (Electronic)
IS  - 0165-1781 (Linking)
VI  - 317
DP  - 2022 Nov
TI  - Anxious-depressive symptoms after a first episode of schizophrenia: Response to 
      treatment and psychopathological considerations from the 2-year "Parma Early 
      Psychosis" program.
PG  - 114887
LID - S0165-1781(22)00479-6 [pii]
LID - 10.1016/j.psychres.2022.114887 [doi]
AB  - Depression is common in schizophrenia and is correlated with suicide risk and 
      poor long-term outcomes. However, the presence of depressive symptoms is often 
      underestimated in both research and treatment, particularly at the illness onset. 
      The goals of this study were: (a) to longitudinally observe anxious-depressive 
      symptom levels in patients with First Episode Schizophrenia (FES) during a 24 
      months of follow-up period, and (b) to examine their associations with other 
      psychopathology and the intervention patients received in an "Early Intervention 
      in Psychosis" (EIP) program during the follow-up period. The Global Assessment of 
      Functioning (GAF) and the Positive And Negative Syndrome Scale (PANSS) were 
      completed by 159 FES patients both at baseline and across the follow-up. Data 
      were analyzed by linear regression analysis and Spearman's coefficients. 
      Anxious-depressive symptoms had significant longitudinal associations with GAF 
      deterioration and PANSS "Positive Symptoms", "Negative Symptoms" and 
      "Disorganization" subscores. During the follow-up period, FES participants 
      significantly improved the level of anxious-depressive symptoms. This was 
      significantly associated with the number of case management and individual 
      psychotherapy meetings the patient engaged in, as well as with lower 
      antipsychotic doses prescribed during the follow-up period. In conclusion, 
      anxious-depressive symptoms are prominent in FES and at the initial entry into 
      EIP programs. Anxious-depressive symptom severity tends to diminish overtime, 
      especially with the provision of specialized EIP treatments. However, since we 
      did not have a control population studied in parallel, we cannot say whether 
      these results are specific to the protocols of EIP programs or just to the 
      intensity of engagement in care.
CI  - Copyright (c) 2022 Elsevier B.V. All rights reserved.
FAU - Pelizza, Lorenzo
AU  - Pelizza L
AD  - Department of Mental Health and Pathological Addiction, Azienda USL di Parma, 
      Largo Palli n. 1/A, Parma 43100, Italy; Department of Biomedical and Neuromotor 
      Sciences, Universita degli Studi di Bologna, Via Zamboni n. 33, Bologna, Italy. 
      Electronic address: lorpelizza@ausl.pr.it.
FAU - Quattrone, Emanuela
AU  - Quattrone E
AD  - Department of Mental Health and Pathological Addiction, Azienda USL di Parma, 
      Largo Palli n. 1/A, Parma 43100, Italy.
FAU - Leuci, Emanuela
AU  - Leuci E
AD  - Department of Mental Health and Pathological Addiction, Azienda USL di Parma, 
      Largo Palli n. 1/A, Parma 43100, Italy.
FAU - Paulillo, Giuseppina
AU  - Paulillo G
AD  - Department of Mental Health and Pathological Addiction, Azienda USL di Parma, 
      Largo Palli n. 1/A, Parma 43100, Italy.
FAU - Azzali, Silvia
AU  - Azzali S
AD  - Department of Mental Health and Pathological Addiction, Azienda USL-IRCCS di 
      Reggio Emilia, Via Amendola n.2, Reggio, Emilia 43100, Italy.
FAU - Pupo, Simona
AU  - Pupo S
AD  - Division of Pain Medicine, Department of Medicine and Surgery, Azienda 
      Ospedaliero-Universitaria di Parma, Via Gramsci n.14, Parma, Italy.
FAU - Pellegrini, Pietro
AU  - Pellegrini P
AD  - Department of Mental Health and Pathological Addiction, Azienda USL di Parma, 
      Largo Palli n. 1/A, Parma 43100, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221005
PL  - Ireland
TA  - Psychiatry Res
JT  - Psychiatry research
JID - 7911385
RN  - 0 (Antipsychotic Agents)
SB  - IM
MH  - Humans
MH  - *Schizophrenia/complications/therapy/diagnosis
MH  - Depression/epidemiology
MH  - *Psychotic Disorders/complications/therapy/diagnosis
MH  - Psychopathology
MH  - *Antipsychotic Agents
MH  - Psychiatric Status Rating Scales
OTO - NOTNLM
OT  - Depression
OT  - Early intervention
OT  - Early schizophrenia
OT  - First episode schizophrenia
OT  - Follow-up
OT  - Treatment response
COIS- Declaration of Competing Interest None.
EDAT- 2022/10/12 06:00
MHDA- 2022/11/18 06:00
CRDT- 2022/10/11 18:25
PHST- 2022/05/17 00:00 [received]
PHST- 2022/10/01 00:00 [revised]
PHST- 2022/10/04 00:00 [accepted]
PHST- 2022/10/12 06:00 [pubmed]
PHST- 2022/11/18 06:00 [medline]
PHST- 2022/10/11 18:25 [entrez]
AID - S0165-1781(22)00479-6 [pii]
AID - 10.1016/j.psychres.2022.114887 [doi]
PST - ppublish
SO  - Psychiatry Res. 2022 Nov;317:114887. doi: 10.1016/j.psychres.2022.114887. Epub 
      2022 Oct 5.